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Abstract
Forty percent of people with Down syndrome exhibit heart defects, most
often an atrioventricular septal defect (AVSD) and less frequently a ventricular
septal defect (VSD) or atrial septal defect (ASD). Lymphoblastoid cell lines
(LCLs) were established from lymphocytes of individuals with trisomy 21, the
chromosomal abnormality causing Down syndrome. Gene expression profiles
generated from DNA microarrays of LCLs from individuals without heart defects
(CHD<sup>-</sup>; n = 22) were compared with those of LCLs from patients with
cardiac malformations (CHD<sup>+</sup>; n = 21). After quantile normalization,
principal component analysis revealed that AVSD carriers could be distinguished
from a combined group of ASD or VSD (ASD+VSD) carriers. From 9,758
expressed genes, we identified 889 and 1,016 genes differentially expressed
between CHD<sup>-</sup> and AVSD and CHD<sup>-</sup> and ASD+VSD,
respectively, with only 119 genes in common. A specific chromosomal enrichment
was found in each...
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Abstract
Forty percent of people with Down syndrome exhibit heart defects, most often an atrioventricular septal defect (AVSD) and
less frequently a ventricular septal defect (VSD) or atrial septal defect (ASD). Lymphoblastoid cell lines (LCLs) were
established from lymphocytes of individuals with trisomy 21, the chromosomal abnormality causing Down syndrome. Gene
expression profiles generated from DNA microarrays of LCLs from individuals without heart defects (CHD2; n = 22) were
compared with those of LCLs from patients with cardiac malformations (CHD+; n = 21). After quantile normalization,
principal component analysis revealed that AVSD carriers could be distinguished from a combined group of ASD or VSD
(ASD+VSD) carriers. From 9,758 expressed genes, we identified 889 and 1,016 genes differentially expressed between CHD2
and AVSD and CHD2 and ASD+VSD, respectively, with only 119 genes in common. A specific chromosomal enrichment was
found in each group of affected genes. Among the differentially expressed genes, more than 65% are expressed in human
or mouse fetal heart tissues (GEO dataset). Additional LCLs from new groups of AVSD and ASD+VSD patients were analyzed
by quantitative PCR; observed expression ratios were similar to microarray results. Analysis of GO categories revealed
enrichment of genes from pathways regulating clathrin-mediated endocytosis in patients with AVSD and of genes involved
in semaphorin-plexin-driven cardiogenesis and the formation of cytoplasmic microtubules in patients with ASD-VSD. A
pathway-oriented search revealed enrichment in the ciliome for both groups and a specific enrichment in Hedgehog and
Jak-stat pathways among ASD+VSD patients. These genes or related pathways are therefore potentially involved in normal
cardiogenesis as well as in cardiac malformations observed in individuals with trisomy 21.
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Introduction
Trisomy 21 (Ts21) or Down syndrome (DS) is the most common
human chromosomal aneuploidy at birth, and the only one with
long-term viability. Congenital heart defects (CHD) are present in
about 40–60% of newborns with DS [1]. Neonatal detection of
cardiac defects followed by cardiac surgery has contributed to
increased life expectancy of individuals with DS.
Cardiac abnormalities in DS include atrioventricular septal
defect (AVSD) (with or without other CHDs), ventricular septal
defect (VSD) (with or without other CHDs), isolated secundum
atrial septal defect (ASD), isolated persistent patent ductus
arteriosus (PDA), and isolated tetralogy of Fallot (TOF). The
reported frequency of each defect varies between studies of
different populations, indicating that genetic background or
consanguinity may affect the CHD phenotype [2–8]. Additionally,
analysis of Ts21 fetal hearts [9], showing that CHD phenotypes
may include the small anomaly called linear insertion of
atrioventricular valves (LIAVV), suggest that the number of
individuals with Ts21 and LIAVV may be underestimated. Most
of the cardiovascular abnormalities associated with Down
syndrome can be detected during fetal development; however,
percentages of cardiac defects detected in fetuses, mostly AVSD
and VSD, vary between studies [10,11]. Cardiac septal defects are
typically observed during the first trimester and are frequently
associated with an increase in nuchal translucency thickness.
The cellular and molecular events that control cardiac
development are conserved among vertebrates. Heart develop-
ment in humans occurs very early, from the third to eight weeks of
gestation, beginning with a primitive tube that beats at 25 days
gestation and ending in the four-chamber heart. Many steps occur
after formation of the primitive heart tube, including looping, cell
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migration, cell transition, and septation events [12–14]. Many
studies indicate that cardiac development is tightly regulated by a
series of molecular signaling pathways and morphological events.
However, many questions remain regarding the changes that
occur to alter heart development in individuals with DS. For
example, it is unclear to what extent secondary changes occur as a
consequence of the aneuploid state, and which environmental
factors combine with genetic causes to induce such changes.
Inter-individual differences in gene expression are likely to
account for an important fraction of phenotypic differences,
including susceptibility to common disorders. Recent studies have
shown extensive variation in gene expression levels in humans and
other organisms, and that a fraction of this variation is under
genetic control [15].
Indeed, the genetic alterations in DS are not as simple as once
believed: while genes on chromosome 21 (HSA21) are transmitted
in 3 copies, all of those genes do not necessarily exhibit a
straightforward 1.5-fold increase in expression. Gene expression
may be regulated by dosage compensation such that only a subset
of those genes exhibit the expected 50% increase in expression. A
previous study using lymphoblastoid cell lines (LCLs) from diploid
(2N) individuals and individuals with Ts21 showed that only 30%
of HSA21 genes are significantly overexpressed [16]. For genes
located on chromosomes other than 21, the effect of Ts21 could be
relatively subtle or massively disruptive.
One hypothesis explaining the complicated genetics of DS
proposes that gene expression changes on HSA21 are likely to
affect the expression of genes on other chromosomes through the
modulation of transcription factors, chromatin remodeling pro-
teins, and related molecules or other targets. Thus, the dysregu-
lation of pathways involved in heart development may cause the
cardiac defects observed in DS. A second hypothesis implicating
both environmental and genetic factors in DS phenotypes is
supported by epidemiological studies of DS: specific cardiac
defects were associated with smoking mothers (AVSD, TOF)
[17,18], folate pathways and folate supplementation have been
proposed to interfere with the incidence of AVSD [19,20], and an
association between DS and CHD with global hypomethylation
status has been found in a Dutch population-based case-control
study [21].
We hypothesized that if the cardiac phenotypes observed in DS
are caused, at least in part, by trisomy-induced gene dosage effects,
it should be possible to genetically differentiate individuals with DS
by their specific heart defects, as well as distinguishing those with
heart defects from those without. Further, such genetic differences
may be manifested in peripheral tissues: dermatoglyphic indicators
used to characterize individuals with DS have been used to
correctly classify them according to their heart status [22].
Several studies have suggested that LCLs can be used to detect
biologically plausible correlations between candidate genes and
various genetically-induced diseases. We collected blood samples
from individuals with DS and controls (2N) and established an
LCL biobank. From this cell bank, we selected LCLs from the
following five types of donors: euploid individuals, individuals with
DS and without CHD, individuals with DS and AVSD,
individuals with DS and ASD, and individuals with DS and
VSD. Microarrays and quantitative PCR were used to identify
differentially expressed (DE) genes. Interestingly, principal com-
ponent analysis was able to distinguish between cells from
individuals with AVSD and those with ASD or VSD (combined
group, hereafter ASD+VSD). Differential expression analyses
allowed us to identify genes and pathways specifically dysregulated
in AVSD and/or ASD+VSD.
Results
Cell lines and phenotypes of each group
Blood samples were collected at five different clinical centers to
establish a Biobank from 190 controls and 550 individuals with
DS. Recorded phenotypes included cardiac defects (AVSD, ASD,
VSD, TOF, PDA, mitral valve prolapsus) and murmurs. To
construct the CHD2 group individuals without murmurs were
selected. For the CHD+ group individuals with only one heart
malformation were selected. For the expression study, samples
were selected from caucasian individuals with DS with the same
age distribution (23.0562.4) for CHD+ and (24.6662.2) for
CHD2. These groups were also created with the same gender
ratio (M/F= 1.1 for CHD+; M/F= 1.2 for CHD2). The same
criteria (ethnicity, age, gender) were used to select a group of 2N
controls.
Differential expression between AVSD and ASD +VSD
Using human pangenomic Illumina microarrays containing
48,701 probes, we obtained expression profiles from 43 samples:
21 from individuals with DS and with a heart defect (CHD+: 7
AVSD, 8 ASD, 6 VSD) and 22 with DS and without heart defect
(CHD2). Among the 48,701 probes on the microarrays, 11,224
probes corresponding to 9,758 genes displayed significant expres-
sion in LCLs. Results from three independent experiments (43
total samples from people with DS) were analyzed to identify DE
genes. Data were normalized using quantile normalization. A first
comparison of gene expression profiles using principal component
analysis (PCA) could not differentiate between the CHD+ and the
CHD2 groups. We thus performed a PCA on the CHD+ group
only. This analysis showed that individuals with DS and AVSD
could be separated from a second group corresponding to
individuals with DS and ASD or VSD (Figure 1). However,
PCA failed to separate between the ASD and VSD groups, even in
the subspace of the first three principal components. A second
analysis of the CHD+ group consisted of two-by-two t-tests with a
global estimate of the common variance, leading to 249 transcripts
with p-value below 0.01 for the AVSD/ASD comparison, 192
transcripts for the AVSD/VSD comparison, and 33 for the ASD/
VSD comparison. We performed a classification of heart defects
(CHD+) according to the distribution frequency of their p-values.
We calculated the empirical cumulative distributions of p-values
for the 2-by-2 Student tests A: AVSD/ASD; B: AVSD/VSD; C:
ASD/VSD. Comparisons were obtained for 11 224 tests. The
comparison to the uniform distribution shows that there is no
overall differential expression between ASD and VSD (less small
p-values than for an uniform distribution).This analysis indicated
that there were no significantly DE genes between ASD and VSD,
and validated our choice to group ASD with VSD for further
analysis (ASD+VSD group) (Figure 2).
Analysis of the data was then performed using ANalysis Of
Variance (ANOVA) on the three following groups: the CHD2
group, the AVSD group, and the ASD+VSD group. We
considered genes with p,0.05 as DE, and, for the latter, we
performed two-by-two comparisons with the CHD2 groups. This
analysis revealed a group of DE genes in AVSD with respect to
CHD2 (889) and a group of DE genes in ASD+VSD with respect
to CHD2 (1016); the two groups exhibited a small overlap (119)
(Table S1).
We also compared cells from 11 CHD2 individuals with DS to
cells from 12 controls (2N individuals) and found 1,766 DE genes
with p,0.05. DS phenotypic variability may be related to
dysregulation of genes with a causative effect (inducing the defect)
or with a protective effect (compensating other negative effects).
Signatures of Cardiac Defects in Down Syndrome
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Detailed analysis of the two groups with heart defects (CHD+ vs.
CHD2) allowed us to group the DE genes into two classes. The
first class (I) contained genes DE in CHD+ (AVSD or ASD+VSD)
with a larger effect between CHD+ and CHD2 than between
CHD2 and 2N; we further divided this class into two sub-classes
(IA, IB) to differentiate genes with similar expression (ratio interval
between 0.95 and 1.05) between CHD2 and 2N individuals (i.e.,
genes that are not dysregulated in CHD2). The second class (II)
contained genes DE in CHD+ with expression levels closer to the
those observed in 2N individuals than to those found in the CHD2
group; we also divided this into two sub-classes (IIA, IIB) to
differentiate genes that presented similar expression (ratio interval
between 0.95 and 1.05) between CHD+ and controls (Table 1 and
Table S2).
Validation by quantitative PCR
We then performed quantitative PCR on a set of LCLs
including the ones analyzed in microarray experiments and LCLs
from other individuals. Two reference genes were selected for
these experiments: hypoxanthine phosphoribosyl transferase
(HPRT) and polymerase (RNA) II (DNA directed) polypeptide A
(POLR2A). Validation experiments were performed on genes
showing high differential expression (ratio .1.3 or ratio ,0.75),
genes selected for their potential functional involvement in heart
development, and genes from clusters on HSA21 (oligonucleotide
sequences are listed in Table S3). We confirmed results obtained
by microarray analysis both for genes with an increased expression
in CHD+ and for genes with a decreased expression in CHD+
(R2 = 0.941, p,0.0001) (Table 2).
Chromosomal localization
We then analyzed the chromosomal localization of DE genes.
Interestingly, genes DE in AVSD as compared to CHD2
preferentially mapped to chromosomes 7, 11, 16, 19, and 20. In
addition, we identified a cluster that contained three contiguous
genes mapped to HSA21: PIGP (DSCR5), TTC3, and DSCR3. A
numerical simulation to compute the probability of finding a
triplet on chromosome 21, assuming that gene expression and
regulation are independent of localization, showed that the triplet
found on HSA21 in the AVSD group was significant (p = 0.039)
(Table S4). These three genes belonged to class IA (genes DE in
AVSD as compared to CHD2 with a larger effect between AVSD
and CHD2 than between CHD2 and 2N, see Table 1). When
Figure 1. Principal component analysis of gene expression profiles of LCLs from individuals with DS and with CHD: red- AVSD
(n=7); green- ASD (n=8); blue- VSD (n=6). Red circle indicates AVSD, blue circle indicates ASD and VSD.
doi:10.1371/journal.pone.0041616.g001
Figure 2. Classification of heart defects (CHD+) according to
the distribution frequency of their p-values. Empirical cumulative
distributions of p-values for the 2-by-2 Student tests A: AVSD/ASD; B:
AVSD/VSD; C: ASD/VSD. Comparisons were obtained for 11 224 tests.
The comparison to the uniform distribution shows that there is no
overall differential expression between ASD and VSD (less small p-
values than for an uniform distribution). Cdf: cumulative distribution
function.
doi:10.1371/journal.pone.0041616.g002
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Table 1. Classification of differentially expressed genes according to heart phenotype and relative expression in Ts21 compared to
2N.
CHD+ categories # DE genes: group I genes: group II genes:
Clusters on
HSA21
|CHD+2CHD2|.|CHD222N| |CHD+2CHD2|,|CHD222N|
A B A B
N probes/n
genes CHD2?2N CHD2=2N CHD+?2N CHD+=2N
p,0.05 (p,0.05) (p$0.05) (p,0.05) (p$0.05)
AVSD 1006/889 295 336 64 0 PIGP-TTC3-DSCR3
(IA)
ASD+VSD 1136/1016 320 327 34 62 IFNAR1-GART-
DONSON (IIA)
Group IA: |CHD+2CHD2|.|CHD222N| and CHD2?2N; Group IB : |CHD+2CHD2|.|CHD222N| and CHD2=2N; Group IIA: |CHD+2CHD2|,|CHD222N| and CHD+?2N;
Group IIB: |CHD+2CHD2|,|CHD222N| and CHD+= 2N.
doi:10.1371/journal.pone.0041616.t001
Table 2. Transcriptome signature of heart defects.
Transcriptome signature of heart malformations
genes array ratios array ratios qPCR ratios
CHD2/2N AVSD/CHD2 AVSD/CHD2
AUTS2 0.86 (NS) 1.83* 1.73*(11/10), 1.55*(10/10), 1.76* (16/16),
1.92*(18/18), 1.81*(18/18)
CNN2 0.9 (NS) 0.69* 0.82*(11/10)
DSCR3 1.21* 1.22* 1.27*(10/10), 1.19*(9/10)
DYNLT3 1.01(NS) 1.42* 1.68*(18/19), 1.71*(17/18)
NQO1 1.57* 0.62* 0.63*(20/19)
OFD1 0.99(NS) 1.39* 1.17 (NS)
PDIA4 1.14(NS) 0.74* 0.7*(11/10), 0.76*(17/17), 0.66*(20/20)
PIGP 1.31* 1.26* 1.35*(10/10), 2.2*(8/9), 1.22*(19/17),
1.31*(17/18)
TTC3 1.35* 1.24* 1.39(12/11), 1.35(10/19), 1.34*(11/12),
1.14*(18/20)
TUBB2B 1.01(NS) 1.79* 1.64*(18/18), 1.8*(18/18)
CHD2/2N ASD+VSD/CHD2 ASD+VSD/CHD2
ACTG1 0.96(NS) 0.63* 0.73*(11/11)
ALDOC 0.87(NS) 1.36* 1.56*(10/10), 1.56*(19/17), 1.54*(19/20)
CACYBP 1.07(NS) 0.73* 0.75*(11/10)
DTYMK 1.00(NS) 0.7* 0.76*(9/9), 0.74*(10/10), 0.8*(11/11)
ENO2 0.89(NS) 1.54* 1.34(NS)
GART 1.39* 0.83* 0.72*(11/11)
IFNAR1 1.21* 0.87* 0.78*(10/10), 0.58* (10/10)
PLTP 1.01(NS) 1.37* 1.32*(10/10)
RPL10A 0.84* 0.64* 0.71*(10/11)
TNFAIP2 1.02(NS) 1.49* 1.5*(9/9)
Comparison of ratios for DE genes up- or down-regulated in the AVSD or ASD+VSD group between (1) array ratio in the Ts21 CHD2 vs 2N, (2) array ratio in CHD+ vs
CHD2, (3) q-PCR ratio from different experiments in CHD+ vs CHD2 using additional samples (total number in parentheses). Gene nomenclature, AUTS2: autism
susceptibility candidate 2; CNN2: calponin 2; DSCR3: Down syndrome critical region gene 3; DYNLT3: dynein, light chain, Tctex-type 3; NQO1: NAD(P)H dehydrogenase,
quinone 1; OFD1: oral-facial-digital syndrome 1; PDIA4: protein disulfide isomerase family A, member 4; PIGP: phosphatidylinositol glycan anchor biosynthesis, class P;
TTC3: tetratricopeptide repeat domain 3; TUBB2B: tubulin, beta 2B; ACTG1: actin, gamma 1; ALDOC: aldolase C, fructose-bisphosphate; CACYBP: calcyclin binding protein;
DTYMK: deoxythymidylate kinase (thymidylate kinase); ENO2: enolase 2 (gamma, neuronal); GART: phosphoribosylglycinamide formyltransferase,
phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase; IFNAR1: interferon (alpha, beta, and omega) receptor 1; PLTP: phospholipid transfer
protein; RPL10A: ribosomal protein L10a; TNFAIP2: tumor necrosis factor, alpha-induced protein 2.
doi:10.1371/journal.pone.0041616.t002
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analyzing genes DE in ASD+VSD as compared to CHD2, we
found an enrichment of genes from chromosomes 11, 19, and 22.
We also found a cluster of genes from HSA21, including IFNAR1,
GART, and DONSON, mapping close to each other. These genes
were from class IIA (genes with expression levels closer to the ones
observed in 2N individuals than to the ones found in the CHD2
group, see Table 1). The triplet on chromosome 21 in the
ASD+VSD group was not significant (Table S4).
Expression pattern, GO category and pathways
enrichment analysis
A list of genes potentially expressed in fetal heart was built from
the human and mouse microarray datasets from GEO. Although
this list is not exhaustive, it allowed us to characterize expression in
the heart as compared to other tissues. We compared this list to
our list of DE genes, and found that 65% of DE genes in AVSD
and 63% of DE genes in ASD+VSD were expressed in the heart
with a significant enrichment (p = 561023 for AVSD and p= 0.01
for ASD+VSD).
Gorilla software was used to calculate the enrichment of GO
categories in DE genes. Comparison of genes expressed in LCLs
(background set) with genes DE in AVSD as compared to CHD2
(target set) showed an enrichment of two GO categories
corresponding to genes involved in the regulation of metabolic
processes and zinc ion binding. Similar analysis performed on DE
genes in ASD+VSD (as compared to CHD2) indicated an
enrichment of three GO categories: biosynthetic processes,
demethylation, and regulation of transcription by glucose (Table 3).
Since pathway analysis is highly dependent on the gene
annotations present in databases, we established lists of genes for
pathways potentially related to heart development (Table S5),
specifically the Wnt, Hedgehog, Notch, and Jak-stat pathways. In
addition, we created lists of genes involved in angiogenesis/
cardiogenesis and in the epithelial-to-mesenchymal transition, i.e.,
genes expressed in the progenitors of the mitral and tricuspid
valves and the membranous interventricular septum since they are
known to arise by an epithelial-mesenchymal cell transformation
(EMT) from embryonic endothelial cells [23],[24]. Among genes
DE in ASD+VSD as compared to CHD2, we found a significant
enrichment in genes belonging or connected to the Hedgehog
pathway and to the Jak-Stat pathway (Table 4, in bold).
Interestingly, we also found a highly significant enrichment in
cilia genes known to be critical for organ laterality and heart
development [25] (and listed from McClintock [26]) among DE
genes in the ASD+VSD cases but also in the AVSD cases (Table 4).
Discussion
Identification of candidate genes or pathways involved in the
occurrence of congenital heart defects in DS has been extensively
pursued, but has failed to provide a clear picture of the genes
responsible for the developmental anomalies observed in individ-
uals with DS. In the mouse, the construction of models carrying
partial trisomies for chromosomal regions orthologous to HSA21
have suggested that (1) trisomy of genes from HSA21—or their
orthologs—may induce heart defects, as shown in Tc1 [27] and
Ts65Dn [28],[29] mice, and (2) specific genes or regions may
contribute heavily to heart defects [30],[31] in the murine models.
In human, attempts to identify candidate genes have compared the
transcriptomes of hearts from fetuses with or without DS [32–34].
However, these studies were performed either without screening
Table 3. GO categories in the CDH+ DE genes.
Heart defects GO Term Description P-value Enrichment (N, B, n, b)
DE [AVSD/CHD2] GO:0008270 zinc ion binding (F) 7.22E-04 1.30 (8259,986,810,126)
GO:0030665 clathrin coated vesicle membrane (C) 7.56E-04 3.71 (8259,22,810,8)
DE [ASD+VSD/CHD2] GO:0016043 cellular component organization (P) 3.14E-05 1.25 (8264,1736,888,234)
GO:0071840 cellular component organization or
biogenesis (P)
3.98E-05 1.25 (8264,1759,888,236)
GO:0071822 protein complex subunit organization
(P)
1.26E-04 1.56 (8264,393,888,66)
GO:0006909 phagocytosis (P) 4.40E-04 3.92 (8264,19,888,8)
GO:0043933 macromolecular complex subunit
organization (P)
4.67E-04 1.42 (8264,551,888,84)
GO:0071526 semaphorin-plexin signaling pathway
(P)
6.06E-04 7.45 (8264,5,888,4)
GO:0007411 axon guidance (P) 6.94E-04 1.90 (8264,132,888,27)
GO:0051592 response to calcium ion (P) 9.90E-04 2.84 (8264,36,888,11)
GO:0032774 RNA biosynthetic process (P) 9.97E-04 1.46 (8264,407,888,64)
GO:0017154 semaphorin receptor activity (F) 1.33E-04 9.31 (8264,4,888,4)
GO:0032991 macromolecular complex (-C) 2.97E-05 1.22 (8264,2220,888,290)
GO:0043234 protein complex (-C) 3.26E-04 1.21 (8264,1789,888,233)
GO:0005881 cytoplasmic microtubule (-C) 3.71E-04 3.64 (8264,23,888,9)
GO:0005829 cytosol (-C) 8.17E-04 1.22 (8264,1521,888,199)
GO:0005829 cytosol (-C) 4.43E-04 1.26 (8256,1388,804,170)
Analysis of the enrichment of GO categories for the genes DE in the comparison between AVSD or ASD+VSD set of genes and CHD2 set of genes compared to the
genes expressed in LCLs. Analysis used GOrilla software with a p-value threshold at 1023. N - is the total number of genes, B - is the total number of genes associated
with a specific null, n - is the number of genes in the group with heart defect, b - is the number of genes in the intersection.
doi:10.1371/journal.pone.0041616.t003
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for heart defects or without differentiating between various heart
defects for a small number of cases and did not lead to the
identification of genes DE in individuals with DS with CHD as
compared to individuals with DS without CHD.
Peripheral tissues carry signatures of heart defects
Using peripheral tissues for analysis of genetic changes allows a
study to assess a larger number of individuals. Recent studies
describe the use of LCLs to characterize expression changes in
various genetic diseases including including Rett syndrome [35],
nonspecific X-linked mental retardation [36], bipolar disorder
[37], autism and fragile X syndrome [38],[39], imprinting diseases
[40], and cardiomyopathy [41]. A recent study of individuals with
mosaicism for trisomy 21 showed that congenital heart defects
were significantly correlated with the percentage of trisomy in
lymphocytes [42]. Here, performing microarray experiments on
RNAs extracted from LCLs of individuals with DS with and
without CHD, we have shown that it was possible to classify DS
carriers of heart defects.
Alteration of signaling pathways differs according to
specific heart defects
Within the group with heart defects (CHD+), it was possible to
differentiate between the transcriptome of cells from individuals
with DS carrying AVSD and those carrying ASD or VSD. With a
p-value below 0.05, 889 genes were DE between AVSD and
CHD2 and 1,016 genes between ASD+VSD and CHD2. The
two groups had a modest overlap of 10–15%, indicating that, for
the most part, different molecular causes contribute to these
morphologically-different cardiac malformations.
Genes that exhibit stronger dysregulation in those with heart
defects are good candidates to explain the defects, particularly
considering alteration of the pathways including or associated with
these genes. However, expression analysis also revealed, at least in
LCLs, the presence of genes (group II) with an expression level
closer to the expression observed in controls than in CHD2: these
results may suggest that over-dysregulation of these genes in
CHD2 exerts a protective effect against the dysregulation of other
genes directly involved in heart defects.
Chromosomal localizations of dysregulated genes is not
always random
Among DE genes located on HSA21, two clusters were
identified: the AVSD cluster (PIGP-TTC3-DSCR3) and the
ASD+VSD cluster (IFNAR1-GART-DONSON). These genes are
included in the narrowed candidate region containing potentially
relevant genes for heart defects in the trisomy 16 mouse models
[31]. Moreover, SNP-to-expression associations have been found
in cis for TTC3 and PIGP(DSCR5) [43]. Screening the
chromosomal location of DE genes revealed an overrepresentation
of genes located on specific chromosomes, specifically chromo-
somes 7, 11, 16, 19, and 20 for the AVSD group and 11, 19, and
22 for the ASD+VSD group. The presence of these contiguous
clusters of genes points to possible common regulatory processes
involved in CHD likely arising from local chromatin modifica-
tions.
Dysregulated genes or pathways are associated with
cardiogenesis and/or cardiac defects
Among DE genes that can be considered as candidate genes
there is a gene encoding an ubiquitin E3 ligase (TTC3).
Interestingly, E3 ligases have been implicated in the etiology of
human cardiovascular diseases: FBXO25 targets cardiac transcrip-
tion factors, indicating that cardiac protein homeostasis has a
pivotal impact on cardiac development that is dependent on the
ubiquitin-proteasome system [44]; increased levels of TTC3 may
interact with similar processes.
There also exist potential synergistic effects. For example, co-
regulation of TTC3 and AUTS2 has been shown during the
differentiation of human embryonic stem cells (hESC) into
cardiomyocytes. TTC3 and AUTS2 are upregulated during the
first step of differentiation of hESC-derived cardiomyocytes into
beating embryoid bodies that highly express cardiac transcrip-
tional regulator genes [45]. Interestingly, TTC3 and AUTS2,
which appear to be involved in common mechanisms, are both
DE in cells from individuals with DS with AVSD.
GO analyses of differential expression in AVSD revealed an
enrichment for genes linked to the formation of clathrin-coated
vesicle membranes; clathrin-mediated membrane trafficking is
essential for cell organisation and likely to be involved in various
steps of heart formation. Additionally, we noted an enrichment in
genes from the semaphorin-plexin signaling pathway for
ASD+VSD: knockdown of semaphorin3D reduces the size of the
primary heart field [46], and semaphorin3C appears to be
regulated by Tbx1, Pitx2, and Gata6—critical regulators of
secondary heart field development [47]; PlexinA1-SemaD6
interaction are involved in myocardial organization and growth
[48].
Enrichment of DE genes in pathways that are known to be
involved in the differentiation of the heart were analyzed more
Table 4. Pathways analysis of DE genes in the CHD+.
LCLs AVSD/CHD
2 ASD+VSD/CHD2
pathways N n enrichment p value n enrichment p value
notch 82 6 0.615 11 0.163
wnt 92 10 0.277 12 0.204
jak-stat 68 7 0.259 12 0.008
hedgehog 37 1 0.912 8 0.012
epithel-mesenchym 31 2 0.673 4 0.23
angiogenesis/cardiogenesis 17 2 0.703 2 0.428
ciliome 1134 134 0.00017 148 0.00027
N is the number of genes from the pathway in genes expressed in LCLs. n is the number of DE genes from the pathway in the AVSD or ASD+VSD set of genes. p is the p
value for the enrichment calculated with 9,758 genes expressed in LCLs, 889 DE genes in AVSD group, and 1,017 DE genes in ASD/VSD group.
doi:10.1371/journal.pone.0041616.t004
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specifically than with the GO approaches. We developed lists of
genes in involved pathways by compiling three different sources
(AMIGO, KEGG, and SAB). We identified an enrichment in the
Hedgehog pathway only in the ASD+VSD group. Hedgehog, and
particularly the Sonic Hedgehog (Shh) pathway, is proposed to be
involved in heart development. Many processes (proliferation/
differentiation, migration, transition) and cell types participate in
heart development, from the heart tube to the four-chamber heart.
Of particular interest are the secondary heart field and neural crest
[49],[50],[51], [52]. The secondary heart field, composed of
different sub-domains, is the target of multiple signals that emerge
from outside the cardiac progenitors. Among these signals,
alteration in the level of Shh secreted by the pulmonary endoderm
may affect the development of the atrial septum [53],[54].
Interestingly, abnormal SHH expression has been observed in
fetuses with DS presenting an increased nuchal translucency [55],
a feature frequently associated with heart defects. Moreover,
altered response to Shh is suggested to be associated to a deficit in
neural crest development in Ts65Dn mice [56]. Thus, Shh
signaling may contribute, via various cells, in the ASD or VSD
anomalies observed in DS.
The Jak-stat pathway was also found to be dysregulated in the
ASD+VSD group. A recent study using Drosophila as a model
system found that Jak-stat controls the expression of tin, a member
of the NK2 transcription factor family, and modulates heart
precursor diversification [57]. Further, a study of proteins secreted
by hESCs identified a potential role of the Jak-stat pathway in
cardiogenesis [58]. Therefore, even subtle alterations in this
pathway could modify very early heart development.
The primary cilium has recently been shown to play a crucial
role in vertebrate development, including that of the heart
[25],[59],[60]. Cilia also appear to be involved in Hedgehog
signaling. Interestingly, although human mutations in cilia genes
were first implicated in LR asymmetry inducing heterotaxy, they
may also lead to heart defects including AVSD, ASD, or VSD, as
in Ellis-van Creveld syndrome [61]. We therefore tested whether
cilia genes were DE in cells from CHD+ individuals as compared
to CHD2. Using the database constructed from mouse cilia genes
[26], we found an enrichment in cilia genes for the two CHD+
groups (AVSD and ASD+VSD), with an overlap of only 16 genes
(12%) between the two sets. Interestingly, TUBB2B and OFD1
(Table 2), as well as the HSA21 gene TSGPA2/RSPH1 (or
meichroacidin [62]) are upregulated in cells from AVSD cases.
Together, the results of this study highlight genes already known
to participate in heart defects, suggest new involvement of specific
pathways in heart morphogenesis, and open new perspectives to
understanding cardiogenic alterations present in individuals with
Down syndrome. Further studies on embryonic samples at
different stages of development will be necessary to identify the
mechanisms at the origin of these different cardiac defects.
Materials and Methods
Individuals and cell lines
LCLs were derived from peripheral blood lymphocytes
collected from individuals with DS by Genethon platform. Parents
of individuals with DS gave written informed consent, and the
French biomedical ethics committees gave their approval for this
study (Comite´ de Protection des Personnes dans la Recherche
Biome´dicale number 03025 and CPP SDE I agreement Nu AC-
2009-12). Heart phenotypes were established from the medical
records either on surgery or echocardiography. Cell lines from
control individuals were also obtained, with written informed
consent, for comparison of chromosome 21 gene expression
profiles. Immortalization was performed in Cell department of
Genethon with the same EBV batch. All cell lines were karyotyped
to confirm their trisomic or euploid status and to verify that
immortalization by the Epstein-Barr virus (EBV) did not produce
any additional chromosomal rearrangement beyond trisomy 21.
Lymphoblastoid cells were grown in Opti-MEM supplemented
with 5% fetal calf serum (Life Technologies) and antibiotics
(Penicilline, Streptomycine).
RNA extraction
Frozen vials from previously immortalized cell lines were
cultured in 5% fetal calf serum in a 5% CO2 incubator. Cells
were harvested at approximately 60% confluency by centrifuga-
tion to a cell pellet of on average 107 cells. The cell pellet was
resuspended in lysis buffer and cell aggregates were dissociated by
careful pipeting, and the Macherey-Nagel mini kit was used to
extract total RNA. RNA was quantified using a NanoDrop and
checked for quality using the Agilent Bioanalyser. Individual
samples were randomised before RNA extraction, amplification,
and hybridisation to Illumina Human WG-6 Sentrix BeadArray
arrays. Arrays were hybridised with labelled cRNA material and
scanned according to manufacturer’s instructions.
Expression data
Expression data were obtained using Illumina Human-6 v2
expression beadchips with 47,701 probes (Illumina Inc., San
Diego, CA) on cRNAs from 21 individuals with heart defects
(CHD+: 7 AVSD, 8 ASD, 6 VSD) and 22 without heart defects
(CHD2). In a second experiment, Illumina Human HT-12 v3
beadchips with 48,803 probes were used to compare 11
individuals with DS without heart defects (CHD2) to 12 controls
(2N individuals). For Illumina BeadArray assay, cRNA (500 ng)
was synthesized with the Illumina RNA Amplification Kit
(Ambion, Austin, TX, USA), purified, labeled, and hybridised
according to the manufacturer’s instructions. Then, arrays were
scanned using the Illumina BeadArray reader (500GX, Illumina),
and scanned images were imported in the BeadStudio software
version 3.1.3.0 (Illumina). For the expression array, unprocessed
data were collected from BeadStudio and processed using
variance-stabilizing transformation (VST) method and quantile
normalization with the R bead array package. Microarray data
have been deposited in GEO database with the number
GSE34459.
Pathways analysis
Gene content of pathways were defined according to three
databases: AMIGO, KEGG, and SAB. Gene lists were construct-
ed by including aliases (GeneCards V3 database, http://www.
genecards.org/).
Real-time quantitative Reverse Transcription PCR
qRT-PCR was used to confirm the results obtained by
expression arrays. The number of samples was increased in
comparison with microarrays to increase the statistical power of
the analysis. cDNAs were synthesized using 1 mg of total RNA
with reverse transcriptase enzyme (Takara, Ozyme) in combina-
tion with oligo-dT and random hexamer priming, and qPCR was
performed as described elsewhere (Roche 480). Primer details are
in Table S3. Expression of the genes of interest was normalized by
using the program. Two normalization genes were selected within
this program: HPRT and POLR2A. Relative quantification was
performed using standard curves, followed by adjustment with a
normalization factor (REST 2009 v2.0.13). Average relative
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expression of genes of interest in studied groups was compared to
controls (either 2N or CHD2).
Statistical analysis
Because they were obtained on two different versions of the
Illumina beadarrays, the expression data sets were analyzed
separately. Both were normalized using quantile normalization, and
expression levels were considered significant when their p-values were
below 1%. Principal component analyses (PCA) were performed on
the transcripts whose expression levels were significant.
In the data set of individuals with DS only, we first analyzed the
subset of 21 individuals with heart defects (CHD+: 7 AVSD, 8
ASD, 6 VSD) with ANOVA, followed by two-by-two t-tests with a
global estimate of the common variance, on the 11,224 transcripts
showing a significant expression level across at least 4 arrays in
each of the three groups. For the ASD/VSD comparison, only 33
transcripts were found differentially expressed (DE), i.e., far less
than expected under the global null hypothesis (112); therefore, the
ASD and VSD group were merged into one, the ASD+VSD
group. Then, a second ANOVA was conducted on the totality of
the first data (22 CHD2, 7 AVSD, and 14 ASD+VSD) again
followed by two-by-two t-tests.
The data set with 11 CHD2 individuals with DS and 12
controls was analyzed with a t-test on the 14,649 transcripts
showing significant expression across at least 9 arrays in each
group.
Supporting Information
Table S1 Differentially expressed genes in LCLs from DS with
and without heart defect.
(XLS)
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ing to their relative level of expression in CHD+ as compared to
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(XLS)
Table S3 Oligonucleotide sequences for qRTPCR. Gene
nomenclature.
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